Full-Time

Electronic Data Interchange Analyst

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Neurovascular and peripheral medical devices manufacturer

Compensation Overview

$100k - $150k/yr

+ Equity

Company Historically Provides H1B Sponsorship

United States

Hybrid

Hybrid role; on-site at headquarters at least 2 times per week.

Bachelor's

Category
Business & Strategy (1)
Required Skills
Word/Pages/Docs
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Penumbra Inc

See people who can refer or advise you

Requirements
  • A Bachelor’s degree in business, computer science, information systems, or a related field, or equivalent relevant work experience
  • 4+ years of EDI experience
  • Experience in the medical device industry dealing with hospital customers
  • Leadership experience in EDI function
  • Strong oral, written and interpersonal communication skills
  • Deep analytical skills
  • High degree of accuracy and attention to detail
  • Proficiency with MS Excel, Word and PowerPoint
  • Excellent organizational skills with ability to prioritize assignments while handling various projects simultaneously
  • Ability to exercise discretion and good judgment with confidential and sensitive information
  • Ability to project manage internal stakeholders
Responsibilities
  • Monitor, troubleshoot, and resolve EDI issues and errors in a timely and efficient manner
  • Act as liaison between our Customer and Field Support Operations (CFSO) team and our IT, Logistics, Finance and Sales teams to resolve EDI issues
  • Collaborate with internal and external stakeholders to increase EDI volume, capabilities, and performance
  • Work directly with customers to facilitate onboarding, offboarding, and issue resolution
  • Provide technical support and guidance to internal users and trading partners on EDI-related matters
  • Demonstrate excellent communication skills (both written and verbal) including the ability to communicate ideas within the team, resolve differences and fully support the customer
  • Demonstrate analytical skills and ability to review EDI data and make recommendations about corrective actions to internal and external stakeholders
  • Maintain and update EDI documentation, standards, and procedures
  • Stay abreast of the latest EDI trends, technologies, and regulations in the healthcare industry
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures
  • Understand relevant security, privacy and compliance principles and adhere to the regulations, standards, and procedures that are applicable to the Company
  • Ensure other members of the department follow the QMS, regulations, standards, and procedures
  • Perform other work-related duties as assigned
Desired Qualifications
  • GHX platform experience is highly desirable
  • Experience in the medical device industry dealing with hospital customers could be considered desirable

Penumbra develops and sells medical devices for neurovascular and peripheral vascular conditions. Its products assist doctors in treating stroke and other vascular diseases by delivering—through systems like the Penumbra System and Indigo System—catheters, coils, and evacuation devices that are placed inside blood vessels. The company differentiates itself with a broad, integrated portfolio and a global sales network across Europe and the Americas, emphasizing engineering and clinical performance. Its goal is to improve patient outcomes and sustain growth by investing in ongoing research and development to expand its capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Get referred to Penumbra Inc

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $390 million, up 14.9%, with 67.9% gross margin.
  • STORM-PE and STRIKE-PE strengthened evidence for CAVT across pulmonary embolism treatment.
  • Embolization and access revenue grew 20.0% in Q2 2026, accelerating beyond thrombectomy.

What critics are saying

  • Boston Scientific's $374-per-share deal closes in 2026, eliminating Penumbra's standalone upside.
  • June 2026 RED 68 catheter recall cites manufacturing fractures, threatening hospital confidence.
  • M&A investigations challenge the merger process, prolonging distraction until shareholder votes and closing.

What makes Penumbra Inc unique

  • THUNDERBOLT won FDA clearance and CE Mark in 2026, extending CAVT leadership.
  • Penumbra operates in over 100 countries, giving unmatched thrombectomy distribution breadth.
  • Magnendo’s $18 million Series A, led by Penumbra, deepens neuro-endovascular robotics optionality.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Jul 30th, 2026
Penumbra reports $390M Q2 revenue, up 14.9% ahead of Boston Scientific acquisition

Penumbra reported second quarter 2026 revenue of $390.0 million, up 14.9% year-over-year. The thrombectomy company's global thrombectomy revenue reached $259.0 million, increasing 12.5%, whilst embolization and access revenue grew 20.0% to $131.1 million. Gross profit margin improved to 67.9%, up 1.9 percentage points from the prior year. Operating income was $41.0 million, with net income of $34.8 million. Total operating expenses stood at $223.9 million, including $6.9 million in acquisition-related costs. Due to Boston Scientific's pending acquisition of Penumbra, the company will not provide full-year 2026 guidance or host a conference call to discuss results. Penumbra operates in over 100 countries, focusing on thrombectomy technologies for conditions including ischaemic stroke and pulmonary embolism.

MarketBeat
Jul 30th, 2026
Penumbra (NYSE:PEN) posts earnings results, misses expectations by $0.27 EPS.

Penumbra (NYSE:PEN) posts earnings results, misses expectations by $0.27 EPS. July 31, 2026 Key points. * Penumbra reported quarterly EPS of $0.88, missing the $1.15 analyst consensus by $0.27, while revenue of $390.05 million slightly exceeded expectations and rose 14.9% year over year. * Shares were essentially unchanged at about $320, with Penumbra valued at $12.59 billion and trading at a price-to-earnings ratio of 83.58. * Institutional investors and hedge funds own 88.88% of the stock, while analysts maintain a consensus "Hold" rating with an average price target of $360.33. * Interested in Penumbra? Here are five stocks we like better. Penumbra (NYSE:PEN - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.15 by ($0.27), FiscalAI reports. The firm had revenue of $390.05 million for the quarter, compared to analysts' expectations of $389.64 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company's revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.86 EPS. Penumbra stock down 0.0%. Shares of PEN traded down $0.04 during midday trading on Thursday, hitting $320.09. The company had a trading volume of 357,942 shares, compared to its average volume of 376,100. The stock has a market cap of $12.59 billion, a price-to-earnings ratio of 83.58, a PEG ratio of 1.98 and a beta of 0.70. The company's 50 day moving average price is $318.89 and its 200 day moving average price is $330.09. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. Penumbra has a 52 week low of $221.26 and a 52 week high of $362.41. Hedge funds weigh in on Penumbra. A number of hedge funds have recently bought and sold shares of PEN. Guggenheim Capital LLC lifted its holdings in Penumbra by 47.5% during the 4th quarter. Guggenheim Capital LLC now owns 3,506 shares of the company's stock worth $1,090,000 after buying an additional 1,129 shares during the last quarter. Stifel Financial Corp increased its holdings in shares of Penumbra by 16.3% in the 4th quarter. Stifel Financial Corp now owns 3,331 shares of the company's stock valued at $1,036,000 after acquiring an additional 466 shares during the last quarter. Perbak Capital Partners LLP raised its position in shares of Penumbra by 152.2% during the 3rd quarter. Perbak Capital Partners LLP now owns 3,773 shares of the company's stock valued at $956,000 after acquiring an additional 2,277 shares in the last quarter. Aviva PLC acquired a new stake in shares of Penumbra during the 4th quarter valued at approximately $518,000. Finally, Vident Advisory LLC lifted its stake in Penumbra by 15.4% during the fourth quarter. Vident Advisory LLC now owns 1,607 shares of the company's stock worth $500,000 after purchasing an additional 215 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds. Analyst upgrades and downgrades. Several equities research analysts recently issued reports on PEN shares. Wall Street Zen raised shares of Penumbra to a "hold" rating in a research note on Saturday, May 9th. Royal Bank Of Canada restated a "sector perform" rating and set a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Penumbra in a research report on Friday, July 17th. Citigroup cut their price target on Penumbra from $374.00 to $350.00 and set a "neutral" rating on the stock in a research note on Thursday, May 7th. Finally, Evercore restated an "outperform" rating and set a $320.00 price objective on shares of Penumbra in a research note on Monday, July 6th. Three research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Penumbra has a consensus rating of "Hold" and an average target price of $360.33. Discover more Stock Market News About Penumbra. Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world. At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Penumbra, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list. While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.

Business Insider
Jul 24th, 2026
Magnendo raises $18M Series A led by Penumbra to advance magnetic robotic stroke intervention system

Magnendo, an MIT spinout developing magnetic robotic navigation technology for neuro-endovascular intervention, has closed an $18 million Series A financing round. The round was led by Penumbra, the thrombectomy company, with participation from new and existing institutional investors. The funding will support productisation of Magnendo's robotic platform and preparation for first-in-human clinical studies. The company's system combines magnetically steerable guidewires with robotic control, medical imaging, and navigation software to help physicians navigate complex vascular anatomy during stroke procedures. Mechanical thrombectomy has transformed acute ischemic stroke treatment, but reaching the treatment site quickly through complex anatomy remains technically demanding. Magnendo's preclinical results suggest the technology could substantially reduce navigation times whilst improving procedural consistency. The company aims to make endovascular procedures faster and more accessible for patients.

Cardiac Vascular News
Jul 24th, 2026
Magnendo secures $18M Series A financing to transform endovascular access for stroke intervention.

Magnendo secures $18M Series A financing to transform endovascular access for stroke intervention. More in financial: Globe Health RSS FeedThis post was originally published on this site NEWTON, Mass., July 24, 2026 (GLOBE NEWSWIRE) - Magnendo Corp., an MIT spinout developing magnetic robotic navigation technology for neuro-endovascular intervention, today announced the closing of an $18 million Series A financing led by Penumbra, Inc., the world's leading thrombectomy company, with participation from a syndicate of new and existing institutional investors. The financing will support the productization of Magnendo's robotic platform and preparation for first-in-human clinical studies. Mechanical thrombectomy has transformed the treatment of acute ischemic stroke, yet rapidly reaching the treatment site remains one of the most technically demanding and time-sensitive aspects of the procedure. Navigating from the vascular access site to the clot through complex and often highly tortuous patient anatomy continues to be a major procedural bottleneck, contributing to prolonged procedure times and poorer outcomes in a significant percentage of patients. Magnendo is developing a robotic system that combines magnetically steerable guidewires with robotic control, advanced medical imaging, and intelligent navigation software to improve endovascular access. The system is designed to help physicians navigate complex vascular anatomy more quickly, consistently, and reliably while remaining compatible with existing clinical workflows and commercially available devices. The company has demonstrated encouraging preclinical results in collaboration with leading neurointerventional physicians, showing the potential to substantially reduce navigation times while improving procedural consistency across operators and anatomies. The proceeds from the Series A financing will support the productization of Magnendo's preclinically validated robotic system and magnetic guidewires and advance the company's first clinical platform toward first-in-human studies. "Our mission is to redefine endovascular access through magnetic robotic navigation, enabling physicians to reach the treatment site faster, more reliably, and with greater consistency," said Yoonho Kim, Ph.D., Founder and CEO of Magnendo. "This financing enables us to accelerate the productization of our preclinically validated platform and prepare for first-in-human studies. We are grateful for Penumbra's confidence in our team and look forward to bringing this technology closer to physicians and patients." "Magnendo has developed an elegant and pragmatic approach to one of the most challenging aspects of endovascular intervention," said Shruthi Narayan, President of Penumbra. "We believe the company's focus on improving navigation while integrating into existing clinical workflows has the potential to meaningfully advance neurovascular care, and we are excited to support the team as they move toward clinical translation." About Magnendo Magnendo Corp. is an MIT spinout developing magnetic robotic navigation technology for endovascular intervention. By combining magnetically steerable guidewires with advanced robotics, medical imaging, and intelligent navigation software, Magnendo aims to help physicians reach the treatment site faster, more reliably, and with greater consistency. Its mission is to make life-saving endovascular procedures faster, safer, and more accessible for every patient. For more information, visit www.magnendo.com or connect on LinkedIn. About Penumbra Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, CardiacVascularNews support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.

MarketBeat
Jul 15th, 2026
Calamos Advisors LLC acquires 62,218 shares of Penumbra, Inc. $PEN.

Calamos Advisors LLC acquires 62,218 shares of Penumbra, Inc. $PEN. July 15, 2026 Key points. * Calamos Advisors LLC dramatically increased its Penumbra stake by 1,334% in Q1, buying 62,218 additional shares and bringing its total holdings to 66,882 shares worth about $21.96 million. * Penumbra reported mixed quarterly results: revenue rose 15.6% year over year to $374.76 million, but EPS of $0.82 missed analyst expectations of $1.06. * Analyst sentiment remains cautious overall, with a Hold consensus rating and an average price target of $360.33, while recent target cuts and downgrades show some division on the stock. * MarketBeat previews the top five stocks to own by August 1st. Calamos Advisors LLC raised its holdings in shares of Penumbra, Inc. (NYSE:PEN - Free Report) by 1,334.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 66,882 shares of the company's stock after buying an additional 62,218 shares during the period. Calamos Advisors LLC owned about 0.17% of Penumbra worth $21,962,000 at the end of the most recent quarter. Several other institutional investors have also added to or reduced their stakes in PEN. State of Michigan Retirement System boosted its stake in shares of Penumbra by 2.2% during the 1st quarter. State of Michigan Retirement System now owns 9,414 shares of the company's stock worth $3,091,000 after acquiring an additional 200 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Penumbra by 5.1% in the 1st quarter. Principal Financial Group Inc. now owns 88,178 shares of the company's stock worth $28,955,000 after purchasing an additional 4,263 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its stake in shares of Penumbra by 2.4% in the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 39,003 shares of the company's stock worth $12,807,000 after purchasing an additional 920 shares in the last quarter. Diversify Wealth Management LLC raised its holdings in Penumbra by 72.0% in the 1st quarter. Diversify Wealth Management LLC now owns 8,283 shares of the company's stock worth $2,691,000 after purchasing an additional 3,467 shares during the period. Finally, Citizens Financial Group Inc. RI raised its holdings in Penumbra by 0.3% in the 1st quarter. Citizens Financial Group Inc. RI now owns 31,254 shares of the company's stock worth $10,263,000 after purchasing an additional 88 shares during the period. 88.88% of the stock is currently owned by institutional investors. Penumbra price performance. NYSE:PEN opened at $316.32 on Wednesday. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. The business's 50-day simple moving average is $320.27 and its two-hundred day simple moving average is $329.78. The stock has a market cap of $12.44 billion, a PE ratio of 72.89, a P/E/G ratio of 1.97 and a beta of 0.70. Penumbra, Inc. has a 52 week low of $221.26 and a 52 week high of $362.41. Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). The business had revenue of $374.76 million during the quarter, compared to analysts' expectations of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. Penumbra's revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.83 earnings per share. As a group, analysts forecast that Penumbra, Inc. will post 5.04 EPS for the current fiscal year. Wall Street analyst weigh in. Several analysts have issued reports on the company. Citigroup cut their price target on Penumbra from $374.00 to $350.00 and set a "neutral" rating for the company in a report on Thursday, May 7th. Evercore reaffirmed an "outperform" rating and issued a $320.00 price objective on shares of Penumbra in a research note on Monday, July 6th. Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Zacks Research cut Penumbra from a "hold" rating to a "strong sell" rating in a research report on Monday, June 29th. Finally, Wall Street Zen upgraded Penumbra to a "hold" rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $360.33. About Penumbra. Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world. At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases. Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN - Free Report). This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Penumbra, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list. While Penumbra currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.